Management of the treatment-naïve patient with HCV infection Paul Desmond Greg Dore.

Slides:

Advertisements

Similar presentations

Christophe Hézode Hôpital Henri Mondor, Créteil, France Paris, 30 January 2012 Triple therapy today: Safety management in clinical practice.

Advertisements

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Practical management of PI therapy in Hepatitis C Paris Februari 2012 Ola Weiland Karolinska Institutet Stockholm, Sweden.

Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.

Management of side effects Cirrhotic on telaprevir Vincent LEROY Clinique Universitaire d’Hépato-Gastroentérologie INSERM U823 CHU de Grenoble.

Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.

Triple Therapy Today: Phase III Results in G1 Relapsers and Nonresponders Bruce R. Bacon, M.D. James F. King MD Endowed Chair in Gastroenterology Professor.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.

No prior therapy with PI

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

Hepatitis web study Hepatitis web study Daclatasvir-Asunaprevir-Beclabuvir in Genotype 1 Cirrhotics UNITY-2 Study Phase 3 Treatment-Naïve and Treatment-Experienced.

Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

Predictors of treatment response, baseline and on-treatment A case study of telaprevir therapy Alex Thompson.

How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

Sulkowski MS, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 23, 2009, Copenhagen, Denmark.04/25/09.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.

Clinical case Laurent CASTERA 5th PHC, Paris, January Service d’Hépatologie Hôpital Beaujon, Université Paris-7, Clichy, France.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.

SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.

SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.

Triple Therapy Today Phase III Results in G1 Relapsers and Non Responders – Telaprevir 5 th Paris Hepatitis Conference Paris, 30. January 2012 Stefan Zeuzem.

SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.

SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, by ITT, descriptive analysis OBV/PTV/r + DSV + RBV No randomisation Open-label CORAL-I Study cohort.

SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)

 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.

Hepatitis web study Hepatitis web study Daclatasvir + Asunaprevir + Peg/RBV in Genotype 1 and 4 HALLMARK-QUAD Study Phase 3 Treatment-Experienced Jensen.

 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.

36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.

Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

No HBV or HIV co-infection

No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection

Design Randomisation* 1 : 1 Open-label W8 W12

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Naïve GT 1-6 POLARIS-2

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

Design No randomisation Open-label W12 W years HCV genotype 1

> 18 years Chronic HCV infection Compensated cirrhosis **

No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

Boceprevir in Treatment Naive SPRINT-2

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

Phase 2b Treatment Naïve and Treatment Experienced

LDV/SOF ± RBV in genotype 3 or 6 – Phase 2

Presentation transcript:

Management of the treatment-naïve patient with HCV infection Paul Desmond Greg Dore

Learning objectives 1.Patient factors involved in treatment decisions 2.Viral factors in treatment decisions 3.Logistics in using DAAs 4.Management of side-effects of DAAs 5.Role of IL-28B testing 6.Role of ribavirin monitoring

Mrs LF 57-year-old housewife Presents to GP with tiredness ALT 65 U/L HCV antibody positive Otherwise well On examination NAD

Mrs LF Risk factors for HCV Husband had liver transplant in 2007 for decompensated HCV/alcohol-related cirrhosis NO IV drug use or blood transfusion

Question What other investigations would you order?

Mrs LF - ALT 62 U/L - Albumin 40 g/L - Platelets 247 x 10 9 /L - HCV PCR Positive - HCV VL 4,730,000 IU/mL - Genotype1a

Questions Genotype 1a vs 1b? Viral load? Influence on response to treatment?

Telaprevir in G1 patients: Impact of host and viral factors Marcellin P, et al. Poster 451; Dusheiko GM, et al. Poster 415. Posters presented at: EASL: The International Liver Congress 2011; March 30-April 3, 2011; Berlin, Germany. Jacobson IM, et al. N Engl J Med. 2011;364: Genotype Race Fibrosis F0-2 F3-F Patients Achieving SVR (%) Results represent telaprevir (T12PR) populations Treatment-naïve GT1 patients Non-BlackBlack 1b 1a Viral load LVL HVL 78 74

GTG (V36) HCV Genotype 1b has a higher genetic barrier than Genotype 1a Subtype 1aSubtype 1b GTG (V36) ATG (V36M) GTCATC (V36) ATCATGATG (V36) (V36M) 1 step 2 steps GTC (V36)

Question Any further investigations?

Mrs LF FibroscanLiver stiffness 7.9 KPa IL28BC/T

Question What should we do now? - Genotype 1a - High viral load - F2-F3 fibrosis - IL28B C/T

Ge*, Fellay*, Thompson* et al. Nature 2009

Multivariate analysis of baseline predictors of SVR (genotype 1 HCV) ITT analysis of patients from IDEAL study who consented to genetic testing, regardless of adherence level (n=1604), plus 67 patients from another trial (race based on self-report, similar to clinical practice setting) Thompson AJ, et al. Gastroenterology. 2010;139: Predictor Adjusted Odds Ratio (95% CI)P Value rs CC5.2 ( )< HCV RNA level ≤ 600,000 IU/mL3.1 ( )< White vs black2.8 ( )< Hispanic vs black2.1 ( ) METAVIR F0-F22.7 ( )< Fasting blood sugar < 5.6 mmol/L1.7 ( )<

Patients (%) 69% SVR 75% 44% TVR 12 + PR PR 48 TVR 8 + PR 63% 66% 38% SVR BOC RGT PR 48 BOC 44 HCV-1 Rx-naïve (ADVANCE/SPRINT-2) TelaprevirBoceprevir

Mrs LF Entered a clinical trial: Telaprevir BD vs Telaprevir TID

Transfusion RBV dose 1000 mg 600 mg End of treatment Mrs LF – Haemoglobin during treatment

Anaemia management on telaprevir Ribavirin dose reduction Transfusion EPO

Mrs LF – Telaprevir side effect (rash)

SIDE EFFECTT12T8PR (T)BOC 44BOC RGTPR (B) Fatigue57%58%57% 53%60% Pruritus50%45%36% Headache41%43%39%46% 42% Nausea43%40%31%43%48%42% Rash37%35%24% Anaemia37%39%19%49% 29% EPO Use43% 24% Insomnia32% 31%33%32%33% Diarrhoea28%32%22% Flu Sx28%29%28%33%36%28% Pyrexia26%30%24%33% 32% Anorectal Sx13%8%4% Dysgeusia43%37%18% TVR & BOC: Adverse events

Treatment of TVR rash RASH Mild Moderate Severe SCAR Emollients, topical corticosteroids, antihistamines, limit sun exposure, loose fitting clothes ? Derm R/V If progresses, cease TVR If no improvement in 7 days, stop RBV Permanently cease TVR Monitor for progression/systemic symptoms If no improvement in 7 days, stop RBV+/- peg-IFN Permanent and immediate cessation of TVR Derm R/V

SCAR (Severe Cutaneous Adverse Reaction) Cacoub P et al. J Hepatol 2012;56: SCAR encompasses several conditions Acute generalised exanthematous pustulosis (AGEP) and Erythema Multiforme Major (EMM) Drug rash/reaction with eosinophilia and systemic symptoms (DRESS) Toxic epidermal necrolysis (TEN) and Stevens- Johnson Syndrome (SJS) 11 cases suggestive of DRESS 3 cases suggestive of SJS (1 case considered not related to telaprevir, onset 11 weeks after telaprevir discontinuation)

Mrs LF – Results on treatment WeekHbNeutrophilsPlateletsALTPCR Neg Neg Neg Neg Neg 48 Neg

Ms CB – Presentation (July 2008) 52-year-old, retired De facto male partner (HCV +ve) 2 children (18, 26 years: HCV –ve) Lives in Far South Coast NSW Smoker: 20 cigarettes/day Alcohol: 40 – 60 grams/day Medications: Nil

Ms CB – Presentation (July 2008) HCV diagnosis: 1995 Risk factors: IDU 1979 – late 2007 Symptoms: mild lethargy Past medical Hx: chronic anxiety Clinical exam: NAD

Ms CB – Baseline investigations (July 2008) LFTs: Alb 44, Bil 8, AST 49, ALT 44, GGT 127 FBC: Hb 153, Neut 3.3, Plats 275 Genotype: 1 (no subtype) HCV RNA: >700,000 IU/ml Fibroscan: 8.1 (November 2008) Management Plan: Alcohol reduction; defer HCV treatment

Ms CB – Follow-up January 2010: Continued alcohol intake g/day No repeat Fibroscan performed October 2011: Continued alcohol intake grams/day Fibroscan: 12.0 kPa Genotype : 1a, HCV viral load 2 million IU/mL LFTS: Alb 44, Bil 7, AST 67, ALT 82, GGT 134 FBC: Hb 148, Neut 2.1, Plats 229 AFP: 26.1

Ms CB – Follow-up February 2012: No further alcohol intake Fibroscan: 13.1 kPa Preparation for HCV treatment Abdominal U/S: NAD No features of cirrhosis/portal H/T No IL28B testing available

Issue 1: Would result of IL28B testing (if available) have influenced choice of treatment regimen?

SPRINT-2: IL28B and DAA response Poordad F, et al. J Hepatol 2011;54(Suppl.):S6 SVR (%) 50/64 n/N= CCTT 44/55 CT 63/7733/116 82/11567/10310/37 26/44 23/42

HCV treatment: peg-IFN/RBV(BOC) April 2012 (baseline): Peg-IFN-alfa-2a (180 mcg/week) + RBV 1000 mg/day LFTs: Alb 41, Bil 7, AST 63, ALT 83, GGT 87 HCV VL:2.08 million (6.3 log)

HCV treatment: peg-IFN/RBV(BOC) May 2012 (week 4): Peg-IFN-alfa-2a (180 mcg/week) + RBV 1000 mg/day AEs: Lethargy, dyspnoea on exertion, insomnia LFTs: Alb 40, Bil 12, AST 43 (63), ALT 44 (83), GGT 124 (87) FBC: Hb 96 (142), Neut 1.4 (2.3), Plats 218 (213) HCV VL:203,400 (5.3) (2,086,900 (6.3) ) RBV conc:2.96

Issue 2: Given the decline in HCV VL over weeks 0 – 4, what is the prospect of SVR? Would the decline in VL influence subsequent treatment?

SPRINT-2: SVR by lead-in viral decline >1 log decline <1 log decline HCV RNA week 0-4 (Non-black) Poordad F, et al. NEJM 2011;364:

Issue 3: Role of EPO vs RBV dose reduction? Role for monitoring of serum RBV concentration?

48 PR (n=363)BOC RGT (n=368)BOC/PR48 (n=366) Median treatment duration, days DeathsN= 4N=1 Serious AEs9%11%12% Discontinued due to AEs16%12%16% Dose modifications due to AEs26%40%35% Haematologic parameters Neutrophil count (< 750 to 500/mm 3 /< 500/mm 3 )14%/4%24%/6%25%/8% Haemoglobin (< 10 to 8.5 g/dl/<8.5 g/dL)26%/4%45%/5%41%/9% Discontinuation due to anaemia1%2% Dose reductions due to anaemia13%20%21% Erythropoietin use24%43% Mean (median) days of use121 (109)94 (85)156 (149) Poordad F, et al. NEJM 2011;364: SPRINT-2: Adverse events

After completion of 4 week peg-IFN/RBV lead In, all patients initiated boceprevir Haemoglobin ≤10 g/dL RBV DR ( mg) EPO (40,000 IU/wk SC) R Haemoglobin ≤8.5 g/dL: Secondary Strategy (EPO, RBV DR, transfusion) R = randomisation DR, dose reduction; EPO, erythropoietin; peg-IFN, peg-interferon; RBV, ribavirin; SC, subcutaneously. EPO vs ribavirin dose reduction in peg-IFN/RBV/BOC HCV treatment naïve, genotype 1 (n=687) Poordad F, et al. EASL 2012

Enrolled n=687 SVR=62.7% (431/687) Met protocol-defined anaemia criteria n=500 SVR=71.2% (356/500) RBV DR and continued peg-IFN/RBV+BOC n=249 SVR=71.5% (178/249) EPO added and continued peg-IFN/RBV+BOC n=251 SVR=70.9% (178/251) Did not meet protocol-defined anaemia criteria (pending randomisation arm) n=187 SVR=40.1% (75/187) Did not meet anaemia criteria; completed peg-IFN/RBV+BOC treatment n=64 SVR=89.1% (57/64) Did not meet anaemia criteria; did not complete treatment n=92 SVR=19.6% (18/92) Discontinued during lead-in n=31 SVR=0% (0/31) Poordad F, et al. EASL %27%

CHARIOT study: RBV conc and SVR (n=210) Ali R, et al. EASL 2011

HCV treatment: peg-IFN/RBV/BOC May 2012 (week 5): RBV reduced from 1000 mg to 600 mg Commenced on BOC (800 mg tds) June 2012 (week 9, (BOC week 4)): Peg-IFN-alfa-2a (180 mcg/week) + RBV (600 mg/day) + BOC (800 mg tds) LFTs: AST 26 (63, 43), ALT 21 (83, 44), GGT 54 (87, 124) FBC: Hb 97 (142, 96), Neut 0.9 (2.3, 1.4), Plats 146 (213, 218) HCV RNA:Undetectable (<15 IU/ml)

Issue 4: Duration of treatment?

SPRINT-2: SVR by treatment arm Non-black (n=938) Black (n=159) Poordad F, et al. NEJM 2011;364:

Mr MD 47-year-old owner/operator of a trucking business HCV diagnosed in 2010 (IV DU 25 years ago) Moderate alcohol intake until 2010 Working fulltime, few symptoms Genotype 1a, viral load 2,230,000 IU/mL ALT 242 U/L Platelets 56, Albumin 24 g/L Varices banded 2011

Genotype 1a Viral load 2,230,000 IU/mL IL28B C/T Fibroscan 42.2 KPa Mr MD

Question Mr MD: Severe cirrhosis Portal hypertension Very active inflammation What can we offer him?